News

Interim Results

Interim Results – Strong underlying growth from key products, on track to meet full year guidance for EBITDA profit in 2017 Click here to view and download our interim results presentation. Read more

Acquisition of Worldwide rights to the Refine™ Support System, an FDA cleared suture based breast-lifting technology

Provides immediate access to a $600 million segment of the US aesthetic market via Thermi’s sales infrastructure Expands and complements Sinclair’s portfolio of premium aesthetics brands London,19 June 2017 Sinclair Pharma plc (SPH.L), (“Sinclair”) the international aesthetics company, is pleased to announce it has acquired the Refine™ Support System, a … Read more

Notice of AGM

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in doubt as to the action to be taken, please consult an appropriately authorised independent financial adviser immediately. If you have sold all of your holdings of ordinary shares in Sinclair IS Pharma Plc you should send this … Read more

Additional Listing announcement

Sinclair Pharma plc Additional listing London, 30 March 2017 Sinclair Pharma plc (SPH.L), (“Sinclair” or the “Company”) the international aesthetics company, announces that 1,570,510 new ordinary shares of 1p each (the “New Ordinary Shares”) have been issued and allotted to Christophe Foucher, former COO, in settlement of his severance package as previously announced … Read more